Every investor in HilleVax, Inc. (NASDAQ:HLVX) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 51% to be precise, is ...

HilleVax, Inc. (NASDAQ:HLVX – Get Free Report) has been given a consensus recommendation of “Hold” by the six analysts that are currently covering the company, MarketBeat.com reports. Six ...

Get the latest HilleVax, Inc. (HLVX) stock news and headlines to help you in your trading and investment decisions.

HilleVax, Inc. is a clinical-stage biopharmaceutical company developing novel vaccines for norovirus, a virus responsible for significant global health and economic burdens.

HilleVax, Inc., a biotechnology company specializing in the development of biological products, has disclosed a significant workforce reduction as part of its ongoing cost-cutting measures. The Boston ...

HilleVax, Inc., a biotechnology company specializing in the development of biological products, has disclosed a significant workforce reduction as part of its ongoing cost-cutting measures. The ...

Get the latest HilleVax, Inc. (HLVX) stock news and headlines to help you in your trading and investment decisions.

BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a ...

HilleVax, Inc., a Boston-based biopharmaceutical company, announced Monday that it has fully repaid its outstanding debt under a loan agreement with Hercules Capital (NYSE: HTGC), Inc.